Pharmacology Shared Resource
The Pharmacology Shared Resource provides preclinical and clinical pharmacologic and pharmacogenetic expertise, methodologies, and services for Mayo Clinic Cancer Center investigators who are developing and evaluating anti-cancer drugs, imaging agents and chemical compounds.
Supported research includes:
- Clinical pharmacokinetic studies conducted within phase I and II trials funded by the National Cancer Institute (NCI) and developed in Mayo Clinic Cancer Center programs, such as the Developmental Therapeutics Program
- Pharmacogenetic studies performed in conjunction with early phase Mayo Clinic Cancer Center clinical trials
- Preclinical pharmacologic studies undertaken by Mayo Clinic Cancer Center investigators as part of NCI-funded grants or to generate data for NCI grant applications
Within the shared resource is state-of-the-art instrumentation, including high-performance liquid chromatography (HPLC), liquid chromatography with tandem mass spectrometry (LC-MS/MS) and real-time polymerase chain reaction (PCR), necessary for preclinical investigations and phase I and II trials.
The Pharmacology Shared Resource contributes to clinical trials sponsored by the Alliance for Clinical Trials in Oncology, Cancer Prevention Network, Phase II Consortium, Children's Oncology Group, National Cancer Institute and Mayo Clinic.
For Mayo Clinic Cancer Center members, the Pharmacology Shared Resource:
- Designs pharmacokinetic studies for clinical trials
- Develops and validates analytical methodologies, such as HPLC, liquid chromatography-mass spectrometry (LC-MS) and mass spectrometry, for the sensitive and specific measurement of drugs and metabolites in biological environments
- Analyzes patient samples for drug and metabolite concentrations in plasma
- Analyzes plasma concentration-time data using compartmental, noncompartmental and population pharmacokinetic methods
- Determines the structure of metabolites and elucidates metabolic pathways
- Develops genotyping methods, such as DNA sequencing and fluorescence-based real-time PCR with SYBR green or TaqMan detection
- Validates methods for determining genetic variants, such as gene frequencies and Hardy-Weinberg equilibrium confirmed with Coriell sample sets
- Determines the presence of allelic variants in patient blood or tumor samples, including paraffin-embedded tissue
- Analyzes genotyping data for genotype-phenotype correlations in collaboration with biostatisticians
Examples of cancer-related studies supported by the Pharmacology Shared Resource include:
- Phase I study of Z-endoxifen as a hormonal therapy for breast cancer
- Single-dose phase 0 exploratory pharmacokinetic clinical trial comparing five oral formulations of SR13668, an orally active Akt pathway inhibitor
- Development of a gold nanoparticle-based targeted delivery system
The Pharmacology Shared Resource is also a critical component of Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis, an NCI-funded U01 grant at Mayo Clinic.
Joel M. Reid, Ph.D.
Pharmacology Shared Resource